Allarity Therapeutics is a precision medicine company specializing in personalized cancer care. As a late clinical-stage brand, they focus on advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Their clinical program consists of five anti-cancer assets in mid- to late-stage clinical development.

One of the key aspects of Allarity Therapeutics is their proprietary Drug Response Predictor (DRP®) technology. This highly accurate technology allows them to refine patient selection and improve clinical outcomes by identifying which patients are more likely to respond to specific drugs. By matching the right patient with the right drug, they aim to increase clinical success rates and transform cancer therapeutic development.

Allarity Therapeutics has a global presence, with headquarters based in Boston, MA, and an R&D facility in Hoersholm, Denmark. Their commitment to enhancing patient outcomes is evident in their approach to value creation, which involves identifying drug candidates with hidden potential, in-licensing candidates with clear efficacy signals, focused development, and exiting programs with significant upside potential. With their proven track record and expertise in personalized cancer care, Allarity Therapeutics strives to make a meaningful impact in the field of oncology